DiaSorin (OTCMKTS:DSRLF) Sees Strong Trading Volume – Should You Buy?

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) saw an uptick in trading volume on Thursday . 300 shares were traded during mid-day trading, an increase of 148% from the previous session’s volume of 121 shares.The stock last traded at $85.78 and had previously closed at $73.85.

Analyst Ratings Changes

A number of brokerages have recently commented on DSRLF. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a research report on Tuesday, February 10th. Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Finally, UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

DiaSorin Price Performance

The stock’s 50-day simple moving average is $68.84 and its two-hundred day simple moving average is $74.48.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.